# US 2013/0273097 A1 · Use of saccharides cross-reactive with bacillus anthracis spore glycoprotein as a vaccine against anthrax

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0273097 A1
- Document ID: US20130273097A1
- Status: Published application
- Kind: A1
- Application number: 13/909,992
- Filed: 2013-06-04
- Published: 2013-10-17
- Earliest claimed: 2008-02-19
- Assignees: National Research Council of Canada; The Gouvernment of the United States of America as Represented by the Secretary of the Department of
- Applicants: National Research Council Canada; The Gouvernment of the United States of America as Represented by the Secretary of the Department of
- Inventors: Joanna Kubler-Kielb; Evguenii Vinogradov; Rachel Schneerson; Haijing Hu; Stephen H. Leppla; John B. Robbins
- Web page: https://patentgrep.com/patent/US20130273097A1

## CPC

- A61K 39/07: Bacillus
- A61K 39/0208: {Specific bacteria not otherwise provided for}
- A61K 39/104: {Pseudomonadales, e.g.} Pseudomonas
- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 31/04: Antibacterial agents
- C07H 3/06: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- C07H 5/04: to nitrogen
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/521: {inactivated (killed)}
- A61K 2039/6081: {Albumin; Keyhole limpet haemocyanin [KLH]}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

Provided are immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacteria that contain 3-methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides. Conjugates of 3-methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides elicit an effective immune response against B. anthracis spores in mammalian hosts to which the conjugates are administered.

## Claims

### Claim 1

A pharmaceutical composition comprising at least one immunogenic agent that is cross-reactive with B. anthracis, wherein the immunogenic agent is selected from:
(a) at least one compound comprising:
(b) an isolated B. anthracis antigenic component from Shewanella or P. syringae;
(c) killed whole cells of Shewanella or P. syringae; or
(d) any combination or mixture of (a)-(c).

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the immunogenic agent is the compound of (a), and the compound of (a) is covalently linked to a polymeric carrier.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the polymeric carrier is a protein.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the immunogenic agent is an isolated B. anthracis antigenic component from Shewanella, and the component is an isolated capsule from Shewanella spp. MR-4.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the immunogenic agent is an isolated B. anthracis antigenic component from P. syringae, and the component is isolated fimbriae from P. syringae.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the immunogenic agent is killed whole cells of Shewanella spp. MR-4.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the immunogenic agent is killed whole cells of P. syringae.

### Claim 8

A pharmaceutical composition comprising at least one compound that is cross-reactive with B. anthracis, wherein the compound comprises
and at least one pharmaceutically acceptable additive.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein the compound is covalently linked to a polymeric carrier.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the polymeric carrier is a pharmaceutically acceptable protein.

### Claim 11 (depends on 9)

The pharmaceutical composition of claim 9, wherein the compound is covalently linked to a carrier selected from bovine serum albumin, recombinant B. anthracis protective antigen, recombinant P. aeruginosa exotoxin A, tetanus toxoid, diphtheria toxoid, pertussis toxoid, C. perfringens toxoid, hepatitis B surface antigen, hepatitis B core antigen, keyhole limpet hemocyanin, or horseshoe crab hemocyanin.

### Claim 12 (depends on 8)

The pharmaceutical composition of claim 8, wherein the additive is an adjuvant.

### Claim 13 (depends on 8)

The pharmaceutical composition of claim 8, wherein the additive is a pharmaceutically acceptable carrier.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, wherein the compound comprises a polysaccharide isolated from a microorganism that is cross-reactive with B. anthracis.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein the microorganism is Shewanella or P. syringae.

### Claim 16 (depends on 14)

The pharmaceutical composition of claim 14, wherein the microorganism is Shewanella spp. MR-4.

### Claim 17

An antibody that is immuno-reactive to a compound comprising
wherein the antibody is also immuno-reactive to B. anthracis spores.

### Claim 18

A vaccine comprising at least one immunogenic agent that is cross-reactive with B. anthracis, wherein the immunogenic agent is selected from:
(a) at least one compound comprising:
(b) an isolated B. anthracis antigenic component from Shewanella or P. syringae;
(c) killed whole cells of Shewanella or P. syringae; or
(d) any combination or mixture of (a)-(c).

### Claim 19 (depends on 1)

A method of inhibiting a Bacillus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 1.

### Claim 20 (depends on 19)

The method of claim 19, wherein the Bacillus is B. anthracis.

### Claim 21 (depends on 19)

The method of claim 19, wherein the immunogenic agent is killed whole cells of Shewanella or P. syringae, and the killed whole cells are administered to a non-human animal that has been, or may have been, exposed to B. anthracis.

### Claim 22 (depends on 19)

The method of claim 19, wherein the subject has been, or may have been, exposed to B. anthracis.

### Claim 23 (depends on 19)

The method of claim 19, wherein the compound is covalently linked to a polymeric carrier.

### Claim 24

A method of inhibiting a Bacillus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of an immunogenic conjugate, the conjugate comprising at least one moiety selected from
covalently linked to a carrier, wherein the conjugate elicits an immune response in a subject.

### Claim 25

A method for stimulating an immune response in a subject against B. anthracis, comprising
selecting a subject in need of stimulating an immune response against B. anthracis; and
administering to the subject at least one immunogenic agent selected from:
(a) at least one compound comprising:
(b) an isolated B. anthracis antigenic component from Shewanella or P. syringae;
(c) killed whole cells of Shewanella or P. syringae; or
(d) any combination or mixture of (a)-(c).

### Claim 26 (depends on 25)

The method of claim 25, wherein the immunogenic agent is the compound of (a), and the compound of (a) is covalently linked to a polymeric carrier.

### Claim 27 (depends on 26)

The method of claim 26, wherein the polymeric carrier is a protein.

### Claim 28 (depends on 25)

The method of claim 25, wherein the immunogenic agent is an isolated B. anthracis antigenic component from Shewanella, and the component is an isolated capsule from Shewanella spp. MR-4.

### Claim 29 (depends on 25)

The method of claim 25, wherein the immunogenic agent is an isolated B. anthracis antigenic component from P. syringae, and the component is isolated fimbriae from P. syringae.

### Claim 30 (depends on 25)

The method of claim 25, wherein the immunogenic agent is killed whole cells of Shewanella spp. MR-4 or killed whole cells of P. syringae.
